Screener
Avalo Therapeutics AVTX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash paid related to withholding shares to satisfy RSU tax withholding obligations | (779) | (509) |
| Proceeds from issuance of common stock under employee stock purchase plan, net of cash paid related to withholding shares to satisfy tax withholding obligations | 66 | 40 |
| Net cash provided by (used in) financing activities | 411,608 | (469) |
| Increase (decrease) in cash, cash equivalents and restricted cash | 69,509 | (92,176) |
| Cash, cash equivalents, and restricted cash at beginning of period | 16,105 | 134,696 |
| Cash, cash equivalents, and restricted cash at end of period | $85,614 | $42,520 |
| Supplemental disclosures of non-cash activities | ||
| Issuance of common stock pursuant to AlmataBio Milestone Buyout Option | $1,761 | — |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's net change in cash?
- Avalo Therapeutics (AVTX) reported net change in cash of $60.3M in Q2 2026.
- How has Avalo Therapeutics's net change in cash changed year-over-year?
- Avalo Therapeutics's net change in cash increased by 172.9% year-over-year, from -$82.72M to $60.3M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Avalo Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude